Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | THRA | P10827 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190078 | 0.89 | MAPK14 (0.43) | MAPK14THRATHRBPOLBFKBP1A | |
| SCHEMBL4197439 | 0.89 | MAPK14 (0.48) | MAPK14THRBPOLBFKBP1AACLY | |
| SCHEMBL4192230 | 0.88 | MAPK14 (0.48) | MAPK14POLBFKBP1AACLYMAP2K1 | |
| SCHEMBL4191639 | 0.81 | MAPK14 (0.45) | MAPK14POLBFKBP1AALDH1A1LMNA | |
| SCHEMBL282039 | 0.74 | THRB (0.53) | THRATHRBPOLBFKBP1AALDH1A1 | |
| SCHEMBL13044591 | 0.67 | THRB (0.57) | THRATHRBALDH1A1 | |
| SCHEMBL13703148 | 0.66 | THRB (0.50) | THRATHRBPOLBALDH1A1LMNA | |
| SCHEMBL13381613 | 0.65 | THRB (0.53) | THRATHRB | |
| SCHEMBL281887 | 0.64 | THRB (0.43) | THRATHRBPOLBFKBP1AALDH1A1 | |
| SCHEMBL13381911 | 0.64 | THRB (0.49) | THRATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | THRA, PYGL, THRB | MAPK14 2562/4885THRA 1/4885THRB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.